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Abstract
Background: Metastatic Adrenocortical Carcinoma (ACC) is a rare malignancy with a poor 5-year-survival rate (<15%).
A surgical approach is recommended in selected patients if complete resection of distant metastasis can be achieved.
To date there are only limited data on the outcome after surgical resection of hepatic metastases of ACC.
Methods: A retrospective analysis of the German Adrenocortical Carcinoma Registry was conducted. Patients with liver
metastases of ACC but without extrahepatic metastases or incomplete tumour resection were included.
Results: Seventy-seven patients fulfilled these criteria. Forty-three patients underwent resection of liver metastases of
ACC. Complete tumour resection (R0) could be achieved in 30 (69.8%). Median overall survival after liver resection was
76.1 months in comparison to 10.1 months in the 34 remaining patients with unresected liver metastases (p < 0.001).
However, disease free survival after liver resection was only 9.1 months. Neither resection status (R0/R1) nor extent of
liver resection were significant predictive factors for overall survival. Patients with a time interval to the first metastasis/
recurrence (TTFR) of greater than 12 months or solitary liver metastases showed significantly prolonged survival.
Conclusions: Liver resection in the case of ACC liver metastases can achieve long term survival with a median overall
survival of more than 5 years, but disease free survival is short despite metastasectomy. Time to recurrence and single
versus multiple metastases are predictive factors for the outcome.
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Background
Adrenocortical Carcinoma (ACC) is a rare malignancy
with an annual incidence of 0.7-2.0 cases per million
population [1] with a poor prognosis [2–4]. Treatment
strongly depends on tumour staging classification sug-
gested by the European Network for Study of Adrenal
Tumours (ENSAT) [5]. Here, primary tumours are clas-
sified into four groups (I-IV). ENSAT stage I and II in-
clude T1 and T2 primary ACC tumours without
lymphatic involvement or distant metastases. Locally ad-
vanced tumours or ACC with lymphatic metastases but
without distant spread are classified as ENSAT stage III.
In these tumour stages, complete resection of primary
tumour as well as regional lymphadenectomy with adju-
vant mitotane therapy is recommended even if multi-
visceral resection is required [2, 6]. Here, disease-specific
5-year-survival rates of 82%, 61% and 13% for stage I, II
and III are reported [5].
Metastatic (ENSAT stage IV) and recurrent ACC disease
exhibit poor 5-survival rates of less than 15% [7]. Neverthe-
less, if complete resection of distant metastases or recurrent
tumour can be achieved, a surgical approach is recom-
mended [7, 8] In a series of 154 patients analysed after first
recurrence, complete resection of recurrent disease led to a
median overall survival of 88 months, when R0 status was
achieved, compared to 11 months in cases in whom surgery
was not possible [9]. Similar results were seen in a recent
series from France with 59 patients [10]. In the case of
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metastatic disease of ACC, the liver is one of the most in-
volved organs beside the lung. In contrast to patients with
isolated liver metastases (LM) of colorectal origin, in which
surgical resection is recommended due to a 5-year overall
survival rate of about 42% after first liver resection [11],
there is as yet only limited data about the value of liver re-
section for non-colorectal, non-neuroendocrine metastases
of other infrequent primary tumours such as ACC [12].
In the present study, we report on a retrospective analysis
with a high case load using the German Adrenocortical
Carcinoma Registry and focusing on a more homogeneous
group of patients with resected and non-resected isolated
liver metastases without extrahepatic manifestation of ACC
origin to proof the value of liver resection for ACC LM.
Methods
Data source
The German Adrenocortical Carcinoma Registry, which
was established in 2003 [13], was used for analysis. Patients
having diagnosis of liver metastases from Adrenocortical
carcinoma until the end of 2015 were involved in this study,
and data of 1031 patients could be included. Clinical data
was collected by trained medical personnel using structured
evaluation forms containing comprehensive information on
diagnostic procedures, surgical outcomes, and follow-up.
The German Adrenocortical Carcinoma Registry was
approved by the ethics committee at the University of
Wuerzburg, and patients gave written informed consent.
Patient selection
From the registry, a total of 306 patients with ACC liver
metastases (29.7%) were identified. Of those, 219 patients
were excluded, while 77 patients, who were at least
18 years of age, met the inclusion criteria of ACC liver
metastases without extrahepatic metastatic disease at the
time of diagnosis and without incomplete resection (R2
including debulking) (Fig.1).
Of the patients included in the study, 43 patients had
undergone radical liver resection under curative
intention between 1985 and 2015. The histologic diagno-
sis for each patient was made by the local pathologist.
The remaining 34 patients with isolated ACC liver
metastases had not undergone liver resection. Reasons
for non-surgical treatment were rarely recorded. Reasons
for this could be missing interdisciplinary tumour con-
ferences in former times, the multicentre setting or a
limited performance status as a reason for patients not
being eligible for liver resection. To consider possible in-
homogeneities characteristics like patient age at diagno-
sis of metastases, sex, side of primary tumour, diameter
of the primary tumour, hormone status of the primary,
the appearance of liver metastases (simultaneous or
secondary), number of liver metastases, the extent of the
surgical procedure and adjuvant therapies like mitotane
were obtained from the registry and in the most cases of
the selected patients directly by review the medical
records. All patients were followed up on a regular basis
(usually every 3 months). Therefore, a complete analysis
of overall and disease free survival was possible.
Statistical analysis
Statistical analysis between the groups was carried out
by using χ2 test for categorical endpoints. A t-test was
used for continuous endpoints. Survival analysis was
Fig. 1 Flow chart of the ACC registry patients and the selection process for patients with liver metastases and no extrahepatic manifestation
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performed using the Kaplan-Meier method and log rank
test. A univariate analysis for relevant prognostic factors
of overall and disease-free survival was performed using
the Cox proportional hazards model. All factors that
showed a trend in overall and disease-free survival in the
univariate analysis (p < 0.1) were further investigated in




Until 2015, 77 patients with liver metastases of ACC but
without extrahepatic manifestation at the time of first
appearance of the liver metastases were identified from
the registry. Mean age at diagnosis of metastases was
49.8 years. There was a significant difference in the
mean age at diagnosis between the group that under-
went liver resection (46.0 years) and the nonsurgical
group (54.7 years) (Table 1). The primary tumour was
equally distributed on both sides. However, liver resec-
tion was performed more frequently, when the primary
was localized on the right side (60.5%). The number of
patients with a primary tumour size of >10 cm was sig-
nificantly higher in the non-resection group (82.4%)
compared to the surgical group (55.8%). In both groups,
around 50% of the carcinomas were hormone-secreting.
However, there was a high percentage of patients with
unknown hormone status in the non-resection group
Table 1 Basic patients’ characteristics
overall Liver resection no Liver resection p-value
n (%) n (%) n (%)
Patiens
overall 77 43 34
female 56 (72.7%) 30 (69.8%) 26 (76.5%) 0.512
Mean age at first diagnosis [y] 49.5 45.5 54.5 0.016
Mean age at diagnosis of liver metastases [y] 49.8 46.0 54.7 0.017
Primary tumour
Localisation
right gland 38 (49.4%) 26 (60.5%) 12 (35.3%) 0.061
left gland 38 (49.4%) 17 (39.5%) 21 (61.8%)
both glands 1 (1.3%) 0 (0.0%) 1 (2.9%)
Diameter
> 10 cm 52 (67.5%) 24 (55.8%) 28 (82.4%) < 0.001
≦ 10 cm 17 (22.1%) 16 (37.2%) 1 (2.9%)
unknown 5 (6.5%) 0 (0.0%) 5 (14.7%)
Hormon status at presentation
functional 38 (49.4%) 21 (48.8%) 17 (50.0%) < 0.001
non-functional 21 (27.3%) 15 (34.9%) 6 (17.6%)
unknown 11 (14.3%) 0 (0.0%) 11 (32.4%)
Liver metastases
Simultaneous liver metastases 33 (42.9%) 13 (30.2%) 20 (58.8%) 0.012
Secondary liver metastases 44 (57.1%) 30 (69.8%) 14 (41.2%)
Time between first diagnosis and liver metastases [m] 43.9 60.5 8.4 0.002
Number
1 35 (45.5%) 26 (60.5%) 9 (26.5%) < 0.001
2-5 12 (15.6%) 7 (16.3%) 5 (14.7%)
> 5 20 (26.0%) 0 (0.0%) 20 (58.8%)
unknown 10 (13.0%) 10 (23.3%) 0 (0.0%)
Systemic therapies after diagnosis of liver metastases
Mitotane 43 (55.8%) 21 (48.8%) 22 (64.7%) 0.164
Chemotherapy 24 (31.2%) 8 (18.6%) 16 (47.1%) 0.007
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(32.4%). 69.8% of resected liver metastases occurred sec-
ondary or metachronous, whereas 58.8% occurred simul-
taneous in the non-resection group. There was also a
significantly higher percentage of patients with solitary
metastases in the resection group. Systemic therapies
after the diagnosis of liver metastases like mitotane or
other chemotherapies were more often applied in the
non-resection group than after resection. Mitotane was
used in 64.7% of patients without liver resection,
whereas it was administered after resection in only
48.8%. Other drugs like etoposide, doxorubicin and cis-
platin were applied in 47.1% and 18.1% respectively
(Table 1).
Liver resection for ACC metastases
In the group of surgical metastasectomy, minor resec-
tions of 1 or 2 segments were most frequently per-
formed regardless of a secondary or simultaneous
approach (Table 2). Histologically confirmed complete
tumour removal (R0 status) was achieved in around 70%
of the cases, with a better performance status when the
procedure was done secondarily. Repeated liver resection
was carry out in one third of the cases.
Overall and disease free survival
After liver resection of metastases of adrenocortical ori-
gin, the median overall survival was 76.1 months in
comparison to 10.1 months in the 34 remaining patients
with unresected liver metastases (p < 0.001) The 5-year
survival rate was 51.3% after surgical therapy vs. 10.7%
in the control group without resection. Nevertheless, the
disease-free survival after liver resection was only
11.1 months with a 5-year disease free survival rate of
20.1%. (Fig.2).
Predictive factors
When comparing the different characteristics between
patients in the resection group, only patients with a time
interval to the first metastasis/recurrence (TTFR) of
greater than 12 months or solitary liver metastases
showed significantly prolong survival (Fig. 3, Table 3). In
the multivariate analysis the hazard ratio continued to
be in the same range (2.455 and 2.876 respectively), but
this was not anymore significant. Neither resection sta-
tus (R0/R1) nor the extent of liver resection (major/
minor) were significant predictive factors for overall sur-
vival. Sex, age, side of primary tumour, size of primary
tumour, hormone status or additive mitotane therapy all
had no significant influence on overall outcome. Appli-
cation of chemotherapies other than mitotane within
3 months after liver resection was associated with even
poorer survival (Table 3). This reflects, however, likely a
selection bias, because 50% of these patients experienced
recurrence of ACC within 3 months after liver resection
and therefore had a poor prognosis on survival.
Significant predictive factors on the disease-free sur-
vival were number of liver metastases, size of primary
tumour and chemotherapy after liver resection (Table 4).
Recurrence after liver resection
Recurrence after the first liver resection of ACC metas-
tases was frequent (88.4%) regardless of the timepoint
(synchronous or metachronous) of metastatic occur-
rence. In 57.9% of cases, recurrence occurred isolated in
Table 2 Liver Resection: Procedural Details
overall secondary resection simultaneous resection
Extend of first liver resection
1 segment 15 (34.9%) 9 (30.0%) 6 (46.2%)
2 segments 13 (30.2%) 8 (26.7%) 5 (38.5%)
mutltiple segments 1 (2.3%) 1 (3.3%) 0 (0.0%)
hemihepatectomy 7 (16.3%) 6 (20.0%) 1 (7.7%)
extended hemihepatectomy 3 (7.0%) 2 (6.7%) 1 (7.7%)
atypical resection 2 (4.7%) 2 (6.7%) 0 (0.0%)
unknown 2 (4.7%) 2 (6.7%) 0 (0.0%)
Resection Status of first liver resection
R0 30 (69.8%) 23 (76.7%) 7 (53.8%)
R1 8 (18.6%) 5 (16.7%) 3 (23.1%)
Rx 5 (11.6%) 2 (6.7%) 3 (23.1%)
Systemic Therapies after first liver Resectiona
Mitotane 21 (48.8%) 17 (56.7%) 4 (30.8%)
Chemotherapy 8 (18.6%) 3 (10.0%) 5 (38.5%)
aApplication within 3 Months after Liver reseection
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Fig. 3 Overall survival after liver resection of ACC liver metastases for patients with (a) 1 or more metastases, (b) time to recurrence of less or greater
than 12 month, (c) R0 and R1 resection and (d) major (>2 segments) or minor liver resection
Fig. 2 a Overall survival (OS) after liver resection for ACC liver metastases in comparison to the non-resected group. b Disease-free survival after liver resection
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the liver, followed by lung (28.9%), abdominal cavity
(18.4%) and bone (7.9%). Multifocal recurrence occurred
in only 10.5% of all resected cases (4/43). There were
only minor differences in the distribution pattern of re-
currence between synchronous and metachronous liver
metastases (Table 5).
Discussion
In this retrospective study, we analysed the benefit of
surgical resection of isolated ACC liver metastases based
on the German ACC registry. Although the registry con-
tained a substantial number of patients with liver metas-
tases of adrenocortical origin, accounting for 29.7%
Table 3 Predictive factors on overall survival after liver resection
Univariate analysis Multivariate analysis
n median survival [mo] HR 95% CI p-value HR 95% CI p-value
Sex
female 30 76.1 1
male 13 58.9 1.066 0.444 - 2.563 0.886
Age at first liver resection (yr)
≤ 50 13 93.3 1
> 50 30 41.6 2.225 0.830 - 5.964 0.112
Occurence of liver metastases
secondary 30 89.3 1
simultaneous 13 23.3 1.485 0.673 - 3.278 0.327
Major liver resection
no 30 57.8 1
yes 11 93.3 0.580 0.226 - 1.488 0.257
Number of liver metastases
1 26 89.3 1 1
> 1 7 35.5 2.620 1.008 - 6.808 0.048 2.455 0.888 - 6.786 0.083
Pathologic margin
R0 30 58.9
R1 8 93.3 1.037 0.372 - 2.889 0.945
Rx 5 92.3 1.127 0.401 - 3.167 0.821
Side of primary tumour
right 26 76.1 1
left 17 89.3 0.772 0.349 - 1.707 0.522
Size of primary tumour (cm)
≤ 10 16 92.3 1
> 10 24 41.6 2.059 0.855 - 4.954 0.107
Secreting primary tumour
no 15 90.3 1
yes 21 42.6 1.624 0.665 - 3.962 0.287
Chemotherapy after liver resection
no 35 90.3 1 1
yes 8 17.3 12.176 3.765 - 39.373 < 0.001 3.453 0.774 - 15.410 0.104
Mitotane after liver resection
no 22 90.3 1
yes 21 57.8 1.010 0.446 - 2.288 0.981
Time to liver metastases [mo]
> 12 25 90.3 1 1
≤ 12 18 23.3 1.983 0.916 - 4.292 0.082 2.876 0.770 - 10.7431 0.116
Baur et al. BMC Cancer  (2017) 17:522 Page 6 of 10
(306/1031) of registered patients, only 77 of these pa-
tients presented with isolated liver metastases and either
received surgical resection or systemic therapies alone.
Irrespective of the number of metastases, our analyses
demonstrate a very high 5-year survival rate of 51.3% in
the 43 liver resected ACC patients. Our data are
consistent with previous studies showing similar outcomes
after resection of hepatic metastases of ACC origin. In a
cohort study of resected non-colorectal and non-
neuroendocrine liver metastases of 28 patients with ACC,
Adam et al. reported a 5-year overall survival of 66% and a
median survival of 63 months after liver resection [14].
Table 4 Predictive factors on disease-free survival after liver resection
Univariate analysis Multivariate analysis
n median survival [mo] HR 95% CI p-value HR 95% CI p-value
Sex
female 30 10.2 1
male 13 7.1 1.062 0.528 - 2.136 0.866
Age at first liver resection (yr)
≤ 50 13 35.5 1
> 50 30 7.1 1.552 0.759 - 3.173 0.229
Occurence of liver metastases
secondary 30 9.1 1
simultaneous 13 7.1 1.309 0.640 - 2.677 0.461
Major liver resection
no 30 7.1 1
yes 11 31.4 0.558 0.256 1.216 0.142
Number of liver metastases
1 26 11.2 1 1
> 1 7 4.1 2.490 1.028 - 6.034 0.043 3.747 1.292 - 10.865 0.015
Pathologic margin
R0 30 10.2 1
R1 8 3.1 1.859 0.827 - 4.175 0.133
Rx 5 73.1 0.809 0.276 - 2.377 0.700
Side of primary tumour
right 26 7.1 1
left 17 15.2 0.710 0.367 - 1.374 0.309
Size of primary tumour (cm)
≤ 10 16 18.2 1 1
> 10 24 7.1 2.034 0.985 - 4.198 0.055 2.764 1.062 - 7.192 0.037
Secreting primary tumour
no 15 13.2 1
yes 21 9.1 1.008 0.490 - 2.071 0.983
Chemotherapy after liver resection
no 35 15.2 1 1
yes 8 3.1 2.844 1.193 - 6.777 0.018 2.568 0.936 - 7.043 0.067
Mitotane after liver resection
no 22 7.1 1
yes 21 10.2 0.994 0.517 - 1.912 0.985
Time to liver metastases [mo]
> 12 25 18.3 1
≤ 12 18 6.1 1.754 0.895 - 3.436 0.102
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Based on these data, ACC patients were ranked as the
most favourable group for liver resection after non-
colorectal and non-neuroendocrine hepatic metastases by
these authors. Based on 19 liver patients with metastatic
ACC, Ripley et al. reported a 5 year overall survival of 29%
after resection, and a 5 year overall survival of 29% pa-
tients (n = 5) that underwent local hepatic thermoablation
(RFA) [15]. Another case report and review of the litera-
ture about thermoablation for ACC LM suggested that
RFA should be considered as therapy alternative only for
patients in whom resection is contraindicated, due to the
increased risk of local recurrence in highly vascularized
ACC metastases after ablation [16]. Weitz et al. analysed
15 patients with ACC and liver metastases with a
40 months cancer specific survival after resection [17]. A
subsequent report from the same institution included 28
patients with ACC LM with a disease-free survival of
7 month and a 5 year survival of 39% [18]. The latter stud-
ies did not exclude patients with extrahepatic tumour
manifestation. Thus, the overall outcomes in these studies
are reasonably poor compared data obtained from our se-
lected resection group which excluded extrahepatic me-
tastases. Additional data on patients presenting ACC LM
suitable for resection but that were never resected is rare
or not available in the literature.
Predictive factors to allocate the patient to radical sur-
gery in case of recurrence, seems to be a time to first re-
currence (TTFR) of greater than 12 months and a solitary
occurrence of liver metastasis. Whereas Erdogan et al. also
identified R0 resection as a predictive factor for prolonged
overall survival in advanced ACC [9], our data did not
show a significant difference between R0 and R1 liver re-
sections. A similar effect was shown for colorectal liver
metastases, where patients with R1 hepatic resection
achieve similar overall survival rates as R0 resected pa-
tients, despite a higher recurrence rate [19]. This fact
could be unique in the case of metastasectomy in the liver.
However, we have to acknowledge that the number of our
study is too small to prove this hypothesis.
Importantly, however, the results of surgical treatment
could not be achieved by nonsurgical therapies alone,
such as mitotane or other chemotherapies. For mitotane
monotherapy in advanced ACC, distinct data about
overall survival in patients without resection is difficult
to obtain. Some reports indicate tumour response rates
of 13% to 33% [20]. However, as recently described in
the FIRM-ACT trial, even the combination of mitotane
with etoposide, doxorubicin and cisplatin (EDP) resulted
in an overall survival of only 14.8 month in advanced
ACC [21]. In addition, the results of other medical ap-
proaches are also of limited or no efficacy [22–27].
Mitotane was shown to have a beneficial effect as adju-
vant treatment after radical resection of primary ACC
[28]. In our study, we did not observe a significant effect
of mitotane in the adjuvant/additive setting after resec-
tion of ACC liver metastases. Despite the low number of
patients, this result might suggest that adjuvant therapy
after metastasectomy of ACC by mitotane or chemother-
apy does not appear to be very beneficial. Similarly, in a
study of 27 patients with synchronously metastatic ACC
Dy et al. observed no apparent impact of chemotherapy
after metastasectomy on overall survival. Nevertheless,
neoadjuvant chemotherapy in the form of mitotane with
or without other chemotherapeutic agents like etopo-
side, doxorubicin and cisplatin was shown to improve
overall survival after resection in 8 patients [29]. Based
on these data, neoadjuvant treatment prior to metasta-
sectomy should be considered as a possible pathway in
further drafts of trials for stage IV ACC.
In the group of liver resection, the site of primary
ACC was more often on the right side (60%), whereas
an equal distribution of the primary ACC to both sides
was observed in all 77 patients with isolated liver me-
tastases. Therefore, direct infiltration of the primary
tumour into the liver on the right side simulating a
solitary metastasis cannot be ruled out for all patients.
However, our data suggest that the side of the primary
had no significant impact on the overall survival after
Table 5 Recurrence after first Liver resection
overall secondary resection simultaneous resection
Recurrence after first liver resection 38 (88.4%) 27 (90.0%) 11 (84.6%)
Median Overall Survival [mo] 57.8 58.9 19.3
Median disease-free survival [mo] 11.1 10.2 11.2
Localisation of Recurrene
Liver 22 (57.9%) 15 (55.6%) 7 (63.6%)
Abdomen 7 (18.4%) 6 (22.2%) 1 (9.1%)
Lung 11 (28.9%) 7 (25.9%) 4 (36.4%)
Bone 3 (7.9%) 2 (7.4%) 1 (9.1%)
multiple Localisations 4 (10.5%) 2 (7.4%) 2 (18.2%)
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liver resection (see Table 3). So, the matter of direct
tumour infiltration can be neglected.
Reliable information about surgical complications in
our study collective could not be obtained from the
register. However, by looking at the length of hospital
stay and a low in-house mortality it can be assumed that
the complication rate of ACC liver metastasectomy is
similar to resection of other secondary liver tumours like
colorectal liver metastases.
Limitations of the study are its retrospective design
and the fact that even after excluding 219 patients
with liver metastases and extrahepatic manifestation
or with incomplete resection, there are still major
differences in the basic characteristics between the
two groups of resected and non-resected patients,
including median age, diameter of the primary
tumour or number of metastases that complicate
objective comparison of overall survival.
Yet, due to the rareness of ACC and the fact that a
large ACC register was the base for this analysis, larger
patient collectives than provided in this study with
resected isolated ACC liver metastases and an additional
corresponding homogenous control group might be hard
to achieve.
Conclusions
Liver resection can achieve long term survival in stage IV
ACC with a 5-year survival rate of 51.3% in this study.
However, disease-free survival seems to be short as the
median disease-free survival is only 9.1 months despite
radical metastasectomy. The main predictive factors for
improved outcome appear to be the interval between pri-
mary tumour manifestation and hepatic recurrence as well
as occurrence of a single versus multiple metastases
within the liver.
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